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Abstract
Background: Herpes simplex virus type-1 (HSV-1) is the primary cause of facial lesions (mouth, lips, and eyes) in
humans. The widespread use of acyclovir and nucleoside analogues has led to emergence of HSV strains that are
resistant to these drugs. Recently, non-nucleoside anti-HSV compounds have received considerable attention. 1,6-
Naphthyridines are a class of heterocyclic compounds that exhibit a broad spectrum of biological activities such as
inhibitor of HIV-1 integrase, HCMV, FGF receptor-1 tyrosine kinase, and the enzyme acetylcholinesterase. We
previously reported the synthesis, SAR studies, and evaluation anti-HSV-1 activity of 3H-benzo[b]pyrazolo[3,4-h]-1,6-
naphthyridines. In the course of our search for new 1,6-naphthyridines derivatives with potential activity against
HSV-1, we have synthesized and evaluated new 3H-benzo[b]pyrazolo[3,4-h]-1,6-naphthyridines (1a-k) and 3H-pyrido
[2,3-b]pyrazolo[3,4-h]-1,6-naphthyridines (2a-c).
Results: A known synthetic approach was used for preparing new 3H-benzo[b]pyrazolo[3,4-h]-1,6-naphthyridines
(1a-k) and 3H-pyrido[2,3-b]pyrazolo[3,4-h]-1,6-naphthyridines (2a-c), starting from ethyl 4-chloro-1-phenyl-1H-
pyrazolo[3,4-b]pyridine-5-carboxylate (7). All compounds were identified by FTIR,
1H NMR, and mass spectrometry.
The antiviral effect on HSV-1 virus replication was determined.
Conclusions: The compounds 1d, 1f, 1g, and 1h exhibited the highest anti-HSV-1 activity. In general, 3H-benzo[b]
pyrazolo[3,4-h]-1,6-naphthyridines were more effective inhibitors than their corresponding 3H-pyrido[2,3-b]pyrazolo
[3,4-h]-1,6-naphthyridines. The compound 1h reduced the virus yield in 91% at 50 μM and exhibited a low
cytotoxicity (CC50 600 μM).
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Background
Herpes simplex virus type-1 (HSV-1) is a large envel-
oped virus containing double-stranded DNA genomes of
approximately 152 kb in size. HSV-1 is the primary
cause of facial lesions (mouth, lips, and eyes) in humans
[1,2]. Most of clinical anti-herpes virus compounds are
nucleoside analogues, such as acyclovir (ACV), which is
the most common drug used on treatment of HSV
infections [3-5]. However, the widespread use of these
compounds has been associated with the emergence of
drug-resistant HSV strains [5]. The discovery of new
non-nucleoside anti-HSV-1 agents with different
mechanisms of action could offer an additional strategy
against drug resistance of viruses. Several examples of
non-nucleoside inhibitors have been proposed as candi-
date drugs for the treatment of herpes [3,6-11].
1,6-Naphthyridines are a class of heterocyclic com-
pounds that exhibit a broad spectrum of biological activ-
ities such as inhibitor of HIV-1 integrase [12-15],
HCMV [16,17], FGF receptor-1 tyrosine kinase [18], and
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the syntheses of 1,6-naphthyridines derivatives have pre-
viously been reported [20-24].
Recently, our research group reported the synthesis,
SAR studies, and evaluation anti-HSV-1 activity of 3H-
benzo[b]pyrazolo[3,4-h]-1,6-naphthyridines derivatives I
(Figure 1) [25]. In the course of our search for new 1,6-
naphthyridines derivatives with potential activity against
HSV-1, we have synthesized and evaluated new 3H-benzo
[b]pyrazolo[3,4-h]-1,6-naphthyridines (1a-k) and 3H-pyr-
ido[2,3-b]pyrazolo[3,4-h]-1,6-naphthyridines (2a-c)
(Scheme 1).
Results and discussion
Chemistry
A known synthetic approach was used for preparing the
3H-benzo[b]pyrazolo[3,4-h]-1,6-naphthyridines (1a-k)
and 3H-pyrido[2,3-b]pyrazolo[3,4-h]-1,6-naphthyridines
(2a-c), starting from ethyl 4-chloro-1-phenyl-1H-pyra-
zolo[3,4-b]pyridine-5-carboxylate (7) (Scheme 1)
[26-28]. In the first step, ethyl a-carboethoxy-b-(5-pyra-
zolylammonium)acrylate (8) was prepared by the con-
densation between 5-amino-1-phenyl-1H-pyrazole (9)
and diethyl ethoxymethylenemalonate, in ethanol. The
cyclization of the acrylate 8 was carried out by refluxing
in phosphorus oxychloride to afford 4-chloro1-phenyl-
1H-pyrazolo[3,4-b]pyridine-5-carboxylate (7) in 75%
yield [26-28]. Nucleophilic displacement of the chlorine
atom in compound 7 by aromatic amines gave ethyl
4-(arylamino)-1-phenyl-1H-pyrazolo[3,4-b]pyridine-5-
carboxylates (5a-k) in yields 52-82% [26,29]. Similarly,
aminopicolines were used to obtain ethyl 4-[(methylpyri-
din-2-yl)amino]-1-phenyl-1H-pyrazolo[3,4-b]pyridine-5-
carboxylates (6a-c) in yields 50-60%. These were
achieved by heating at 140°C without solvents for 2-4 h
an equimolar mixture of the appropriate aniline or ami-
nopicoline and the compound 7. However, better results
were obtained when these reactions were carried out in
solvents such as DMF [25]. Subsequent hydrolysis of
the esters 5a-k and 6a-c afforded the corresponding
4-(arylamino)-1-phenyl-1H-pyrazolo[3,4-b]pyridine-5-
carboxylic acids (3a-k) and 4-[(methylpyridin-2-yl)
amino]-1-phenyl-1H-pyrazolo[3,4-b]pyridine-4-car-
boxylic acids (4a-c), in high yields, 86-93 and 80-93%,
respectively [28]. For producing 3H-benzo[b]pyrazolo
[3,4-h]-1,6-naphthyridines (1a-k) and 3H-pyrido[2,3-b]
pyrazolo[3,4-h]-1,6-naphthyridines (2a-c),t h er e s p e c t i v e
carboxylic acids 3a-k and 4a-c were cyclized with phos-
phorus oxychloride at 110°C over a period of 3 h
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Figure 1 Structure of 3H-benzo[b]pyrazolo[3,4-h]-1,6-naphthyridines I previously evaluated against HSV-1.
Scheme 1 Synthetic approach used to obtain the 3H-benzo[b]
pyrazolo[3,4-h]-1,6-naphthyridine derivatives (1a-k), and new three
3H-pyrido[2,3-b]pyrazolo[3,4-h]-1,6-naphthyridine derivatives (2a-c).
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isolated in 60-70% yield.
Biological evaluation
The targets 3H-benzo[b]pyrazolo[3,4-h]-1,6-naphthyri-
dines (1a-k) and 3H-pyrido[2,3-b]pyrazolo[3,4-h]-1,6-
naphthyridines (2a-c) were evaluated for inhibition of
HSV-1 replication in infected Vero cells. Results are
shown in Table 1. Compounds 1d, 1f, 1g,a n d1h exhib-
ited the highest anti-HSV-1 activity. Compound 1h
reduced the virus yield in 91% at 50 μM. In general, 3H-
benzo[b]pyrazolo[3,4-h]-1,6-naphthyridines (1a-k) were
more effective inhibitors than their corresponding 3H-pyr-
ido[2,3-b]pyrazolo[3,4-h]-1,6-naphthyridines (2a-c).
Compounds with nearly the same antiviral effects were
evaluated for cytotoxicity in Vero cells. EC50 and the selec-
tivity index (SI) were determined in parallel. Several of the
new compounds prevented the cytopathic effect of HSV-1
in Vero cells, at micromolar concentrations, and were
minimally toxic to Vero cells resulting in a good SI. The
MTT assay indicated that compound 1h exhibited a low
cytotoxicity (CC50 600 μM). Trypan blue and MTT
showed similar results (data not shown). ACV results have
been included for comparison purposes (Table 2).
Conclusions
In summary, a new series of 3H-benzo[b]pyrazolo[3,4-h]-
1,6-naphthyridines (1a-k) and 3H-pyrido[2,3-b]pyrazolo
[3,4-h]-1,6-naphthyridine (2a-c) were synthesized and
some of them were potent anti-HSV-1 agents. The
compounds 1d, 1f, 1g, and 1h exhibited the highest anti-
HSV-1 activity, being the 3H-benzo[b]pyrazolo[3,4-h]-1,6-
naphthyridine derivatives, in general, more effective inhibi-
tors than their corresponding 3H-pyrido[2,3-b]pyrazolo
[3,4-h]-1,6-naphthyridines. The compound 1h reduced the
virus yield in 91% at 50 μM and exhibited a low cytotoxicity
(CC50 600 μM). The mechanism of antiviral activity of
these compounds is under investigation.
Experimental
Melting points were determined on a Fisatom 430D and
are uncorrected.
1H NMR spectra were recorded on a Var-
ian Unity Plus spectrometer for 300 MHz, with tetra-
methylsilane as the internal standard. Chemical shifts (δ)
are reported in parts per million (ppm) and the coupling
constants (J) in Hertz (Hz). Fourier transform infrared
absorption spectra were recorded in a Perkin-Elmer Spec-
trum One FTIR spectrophotometer. The solid samples
were measured using potassium bromide (KBr) pellets.
Thin-layer chromatography was performed on Uniplates
(silica gel). All chemicals were reagent grade. High-resolu-
tion mass spectral analysis was recorded using a Finingan
MAT 711A.
General procedures for the synthesis of 3H-benzo[b]
pyrazolo[3,4-h]-1,6-naphthyridine derivatives (1a-k), and
3H-pyrido[2,3-b]pyrazolo[3,4-h]-1,6-naphthyridine
derivatives (2a-c)
The key intermediate ethyl 4-chloro-1-phenyl-1H-pyra-
zolo[3,4-b]pyridine-5-carboxylate (7) was prepared
according to literature [26-28]. An equimolar mixture of
7 (4 mmol) and anilines or aminopicolines in 10 mL
DMF was heated under reflux for 2-4 h. The reaction
mixture, after cooling, was poured into 50 mL of ice-
water. The precipitated was filtered, dried, and recrystal-
lized from a mixture of ethanol and water. The com-
pounds obtained 5a-k and 6a-c were reacted with 10 mL
NaOH (20%) and 10 mL of ethanol under reflux for 1-3
h. On cooling to room temperature, the mixture was
acidified with diluted hydrochloric acid (1:3), and the
precipitate was filtered and recrystallized from DMF and
Table 1 Anti-HSV-1 activity of 3H-benzo[b]pyrazolo[3,4-
h]-1,6-naphthyridines (1a-k) and 3H-pyrido[2,3-b]pyrazolo
[3,4-h]-1,6-naphthyridines (2a-c)
Compound R % of inhibition of virus yield (HSV-1)
1a H 20,6
1b 9-OCH3 50,0
1c 9-CH3 68,0
1d 9-Cl 80,0
1e 8-Cl 60,0
1f 9-NO2 80,0
1g 8-NO2 87,0
1h 9-F 91,0
1i 8-F 65,0
1j 9-Br 30,0
1k 8-Br 30,0
2a 7-CH3 11,0
2b 8-CH3 ND
2c 9-CH3 65,0
ACV - 96.0 ± 1.0
The experimental concentration of 1a-k and 2a-c was 50 μM and for ACV
10 μM.
Results are presented as the mean of triplicate experiments.
ACV has been included for comparison purposes.
Table 2 Anti-HSV-1 activity, cytotoxicity and SI in Vero
cells for 6-chloro-3-phenyl-9-fluoro-3H-benzo[b]pyrazolo
[3,4-h]-1,6-naphthyridine (1h)
Compounds R EC50
a (μM) CC50
b (μM) S.I.
c
1h 9-F 0,07 600 8571
ACV 1.09 ± 0.25 960 ± 156 880
ACV has been included for comparison purposes.
a50% Effective concentration or concentration required to inhibit HSV-1 virus
yield.
b50% Cytotoxic concentration or concentration required to reduce the
viability of host cells by 50%.
cSelective index (CC50/EC50).
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and phosphorus oxychloride (5 mL) was heated under
reflux for 3 h. The reaction mixture was inverted over
crushed ice. In some cases the excess of phosphorus oxy-
chloride was removed under reduced pressure before
inverting over crushed ice and neutralized. The new
compounds 1a-k and 2a-c were isolated in yields
60-70%. The resulting precipitate was collected and puri-
fied by flash column chromatography (FC, silica gel). The
structures of the compounds were elucidated by FTIR,
1H NMR, and mass spectrometry.
(1a) 6-chloro-3-phenyl-3H-benzo[b]pyrazolo[3,4-h]-1,6-
naphthyridine
Yield 70%; mp 259-260°C; IR (KBr, cm
-1) νmax C-H
3084, C = C 1596, C = N 1502;
1H NMR (DMSO-d6,
300 MHz) δ 8.92 (1H, s, H-1), 8.40 (1H, d, J =8 . 1H z ,
H-10), 7.95 (1H, dd; J = 8.1 Hz, H-9), 7.70 (1H, dd, J =
8 . 1H z ,H - 8 ) ,7 . 8 1( 1 H ,d ,J = 8.1 Hz, H-7), 9.40 (1H, s,
H-5), 8.33 (2H, d, J =7 . 5H z ,H - 2 ’,H - 6 ’), 7.50 (2H, t,
J =7 . 5H z ,H - 3 ’,H - 5 ’), 7.52 (1H, t, J =7 . 5H z ,H - 4 ’); EI
(70eV) m/z (%): M
+ 330.00761 (100).
(1b) 6-chloro-3-phenyl-9-methoxy-3H-benzo[b]pyrazolo
[3,4-h]-1,6-naphthyridine
Yield 68%; mp > 300°C; IR (KBr, cm
-1) νmax C-H 3083,
C = C 1595, C = N 1504;
1H NMR (DMSO-d6, 300
MHz) δ 8.99 (1H, s, H-1), 7.26 (1H, s, H-10), 7.78-7.56
(5H, m, H-3’,H - 4 ’,H - 5 ’,H 7 ,H - 8 ) ,9 . 3 6( 1 H ,s ,H - 5 ) ,
8.31 (2H, d, J =8 . 0H z ,H - 2 ’,H - 6 ’), 4.07 (3H, s, Ar-
OCH3); EI (70 eV) m/z (%): M
+. 360.07037 (100).
(1c) 6-chloro-3-phenyl-9-methyl-3H-benzo[b]pyrazolo
[3,4-h]-1,6-naphthyridine
Yield 65%; mp > 300°C; IR (KBr, cm
-1) νmax C-H 3083,
C = C 1595, C = N 1503;
1H NMR (DMSO-d6, 300
MHz) δ 8.99 (1H, s, H-1), 7.79-7.57 (6H, m, H-3’,H - 4 ’,
H-5’, H7, H-8, H-10), 9.42 (1H, s, H-5), 8.40 (2H, d, J =
8.4 Hz, H-2’,H - 6 ’), 1.39 (3H, s, Ar-CH3); EI (70eV) m/z
(%): M
+. 344.81022 (100).
(1d) 6,9-dichloro-3-phenyl-3H-benzo[b]pyrazolo[3,4-h]-
1,6-naphthyridine
Yield 60%; mp > 300°C; IR (KBr, cm
-1) νmax C-H 3082,
C = C 1598, C = N 1503;
1H NMR (DMSO-d6, 300
MHz) δ 9.08 (1H, s, H-1), 7.99-7.53 (6H, m, H-3’,H - 4 ’,
H-5’, H7, H-8, H-10), 9.38 (1H, s, H-5), 8.41 (2H, d, J =
8.4 Hz, H-2’,H - 6 ’); EI (70 eV) m/z (%): M
+. 364.01693
(100).
(1e) 6,8-dichloro-3-phenyl-3H-benzo[b]pyrazolo[3,4-h]-1,6-
naphthyridine
Yield 68%; mp > 300°C; IR (KBr, cm
-1) νmax C-H 3084,
C = C 1598, C = N 1503;
1H NMR (DMSO-d6, 300
MHz) δ 8.97 (1H, s, H-1), 7.87 (1H, d, J =8 . 1H z ,H -
10), 7.89 (1H, d, J = 8.1 Hz, H-9), 8.22 (1H, s, H-7), 9.31
(1H, s, H-5), 8.27 (2H, d, J =8 . 1H z ,H - 2 ’,H - 6 ’), 7.46
(2H, dd, J =7 . 5H z ,H - 3 ’,H - 5 ’), 7.65 (1H, t, J =7 . 5H z ,
H-4’); EI (70 eV) m/z (%): M
+. 364.01789 (100).
(1f) 6-chloro-3-phenyl-9-nitro-3H-benzo[b]pyrazolo[3,4-h]-
1,6-naphthyridine
Yield 60%; mp > 300°C; IR (KBr, cm
-1) νmax C-H 3084,
C = C 1596, C = N 1503;
1H NMR (DMSO-d6, 300
MHz) δ 8.92 (1H, s, H-1), 8.84 (1H, s, H-10), 8.05 (1H,
d, J = 7.5 Hz, H-8), 8.02 (1H, d, J =7 . 5H z ,H - 7 ) ,9 . 4 0
(1H, s, H-5), 8.31 (2H, d, J =7 . 5H z ,H - 2 ’,H - 6 ’), 7.52
(2H, dd, J =7 . 5H z ,H - 3 ’,H - 5 ’), 7.71 (1H, t, J =7 . 5H z ,
H-4’); EI (70 eV) m/z (%): M
+. 375.03743 (100).
(1g) 6-chloro-3-phenyl-8-nitro-3H-benzo[b]pyrazolo[3,4-h]-
1,6-naphthyridine
Yield 60%; mp 280-281°C; IR (KBr, cm
-1) νmax C-H
3100, C = C 1592, C = N 1500;
1H NMR (DMSO-d6,
300 MHz) δ 8.90 (1H, s, H-1), 8.12 (1H, d, J =7 . 8H z ,
H-10), 8.80 (1H, d, J = 7.8 Hz, H-9), 8.89 (1H, s, H-7),
9.42 (1H, s, H-5), 8.30 (2H, d, J =7 . 5H z ,H - 2 ’,H - 6 ’),
7.51 (2H, dd, J =7 . 5H z ,H - 3 ’,H - 5 ’), 7.68 (1H, t, J =7 . 5
Hz, H-4’); EI (70 eV) m/z (%): M
+. 375.70261 (100).
(1h) 6-chloro-3-phenyl-9-fluoro-3H-benzo[b]pyrazolo[3,4-
h]-1,6-naphthyridine
Yield 62%; mp 275-277°C; IR (KBr, cm
-1) νmax C-H
3100, ν C = C 1600, ν C = N 1503;
1H NMR (DMSO-
d6, 300 MHz) δ 9.34 (1H, s, H-1), 8.45 (1H, s, H-10),
7.83-7.62 (1H, m, H-8), 9.02 (1H, d, J =8 . 4H z ,H - 7 ) ,
9.49 (1H, s, H-5), 8.20 (2H, d, J =7 . 5H z ,H - 2 ’,H - 6 ’),
7.25 (2H, dd, J =7 . 5H z ,H - 3 ’,H - 5 ’), 7.41 (1H, t, J =7 . 5
Hz, H-4’); EI (70 eV) m/z (%): M
+. 348.04188 (100).
(1i) 6-chloro-3-phenyl-8-fluoro-3H-benzo[b]pyrazolo[3,4-
h]-1,6-naphthyridine
Yield 65%; mp 278-279°C; IR (KBr, cm
-1) νmax C-H
3051, C = C 1598, C = N 1503;
1H NMR (DMSO-d6,
300 MHz) δ 9.06 (1H, s, H-1), 8.03 (1H, d, J =7 . 5H z ,
H-10), 8.05 (1H, m, H-9), 8.02 (1H, d, J =8 . 4H z ,H - 7 ) ,
9.37 (1H, s, H-5), 8.32 (2H, d, J =7 . 5H z ,H - 2 ’,H - 6 ’),
7.51 (1H, t, J =7 . 5H z ,H - 4 ’), 7.69 (2H, dd, J =7 . 5H z ,
H-3’, H-5’); EI (70 eV) m/z (%): M
+. 348.09473 (100).
(1j) 9-bromo-6-chloro-3-phenyl-3H-benzo[b]pyrazolo[3,4-
h]-1,6-naphthyridine
Yield 60%; mp > 300°C; IR (KBr, cm
-1) νmax C-H 3052,
C = C 1593, C = N 1503;
1H NMR (DMSO-d6, 300
MHz) δ 9.05 (1H, s, H-1), 8.09 (1H, s, H-10), 7.90-7.50
(5H, m, H-3’,H - 4 ’,H - 5 ’,H 7 ,H - 8 ) ,9 . 3 0( 1 H ,s ,H - 5 ) ,
8.30 (2H, d, J =7 . 5H z ,H - 2 ’,H - 6 ’); EI (70 eV) m/z (%):
M
+. 409.96178 (100).
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h]-1,6-naphthyridine
Yield 68%; mp > 300°C; IR (KBr, cm
-1) νmax C-H 3085,
C = C 1596, C = N 1501;
1H NMR (DMSO-d6, 300
MHz) δ 8.95 (1H, s, H-1), 7.92-7.52 (5H, m, H-3’,H - 4 ’,
H-5’, H7, H-10), 8.42 (1H, d, J = 8.4 Hz, H-9), 9.40 (1H,
s, H-5), 8.30 (1H, d, J =7 . 5H z ,H - 2 ’,H - 6 ’); EI (70 eV)
m/z (%): M
+. 409,67991 (100).
(2a) 6-chloro-3-phenyl-7-methyl-3H-pyrido[2,3-b]pyrazolo
[3,4-h]-1,6-naphthyridine
Yield 60%; mp 230-232°C; IR (KBr, cm
-1) νmax C-H
3085, C = C 1596, C = N 1501;
1H NMR (DMSO-d6,
300 MHz) δ 8.72 (1H, s, H-1), 8.26 (1H, d, J =7 . 5H z ,
H-9), 7.68 (1H, d, J = 7.5 Hz, H-8), 9.44 (1H, s, H-5),
8.26 (2H, dd, J =7 . 5H z ,H - 2 ’,H - 6 ’), 7.50 (1H, t, J =7 . 5
Hz, H-4’), 7.68 (2H, dd, J =7 . 5H z ,H - 3 ’,H - 5 ’), 1.37
(3H, s, Ar-CH3); EI (70eV) m/z (%): M
+. 345.74391
(100).
(2b) 6-chloro-3-phenyl-8-methyl-3H-pyrido[2,3-b]pyrazolo
[3,4-h]-1,6-naphthyridine
Yield 65%; mp 255-256°C; IR (KBr, cm
-1) νmax C-H
3084, C = C 1596, C = N 1502;
1H NMR (DMSO-d6,
300 MHz) δ 8.72 (1H, s, H-1), 8.92 (1H, s, H-9), 7.91
(1H, s, H-7), 9.58 (1H, s, H-5), 8.42 (2H, d, J =7 . 5H z ,
H-2’, H-6’), 7.59 (1H, t, J = 7.5 Hz, H-4’), 7.78 (2H, dd, J
=7 . 5H z ,H - 3 ’,H - 5 ’), 1.42 (3H, s, Ar-CH3); EI (70 eV)
m/z (%): M
+. 345.78660 (100).
(2c) 6-chloro-3-phenyl-9-methyl-3H-pyrido[2,3-b]pyrazolo
[3,4-h]-1,6-naphthyridine
Yield 62%; mp 247-249°C; IR (KBr, cm
-1) νmax C-H
3084, C = C 1596, C = N 1502;
1H NMR (DMSO-d6,
300 MHz) δ 8.83 (1H, s, H-1), 7.67 (1H, d, J =7 . 5H z ,
H-8), 7.93 (1H, d, J = 7.5 Hz, H-7), 9.41 (1H, s, H-5),
8.39 (2H, d, J =7 . 5H z ,H - 2 ’,H - 6 ’), 7.56 (1H, t, J =7 . 5
Hz, H-4’), 7.75 (2H, dd, J =7 . 5H z ,H - 3 ’,H - 5 ’), 1.39
(3H, s, Ar-CH3); EI (70 eV) m/z (%): M
+. 345.76572
(100).
Biological assays
Compounds were tested as inhibitor of HSV replication in
Vero (African green monkey kidney, obtained from the
American Type Culture Collection) cells. They were
grown in DMEM (Gibco Laboratories) supplemented with
2% heat-inactivated fetal bovine serum (purchased from
Fazenda Pig), 8% calf serum (purchased from Centro Pan-
Americano de Febre Aftosa), 2.25% sodium bicarbonate,
500 U/mL penicillin, 100 μg/mL streptomycin, and 2.5 μg/
mL amphotericin B. HSV-1 (ACR-29 strain) was kindly
provided by Marcia Wigg (Universidade Federal do Rio de
Janeiro, Brazil) and was routinely propagated in Vero cells.
Virus stocks were stored at -70°C until use. ACV was
purchased from Sigma (A 4669). It was dissolved in sterile
deionized water and further diluted in culture medium.
MTT was purchased from Sigma. Virus infectivity was
measured by a dilution method using a 96-well microtitre
plate and expressed as 50% tissue culture infections dose
(TCID50). Cells grown in 96-well microtitre were inocu-
lated with virus at input 1 PFU (plaque-forming unit)/cell
for 2 h at 37°C. After virus adsorption, virus inoculum was
replaced by a culture medium containing quinolone acy-
clonucleobases carboxylic acid and their correspondent
esters at the concentration of 50 μM. Control cultures
were incubated with media without compounds. After 3
days of incubation at 37°C in 5% CO2 atmosphere, the cul-
ture medium was harvested and the virus titre of each
sample was determined in terms of 50% tissue culture
dose (TCID 50/mL) by endpoint dilution.
Cytotoxicity
The cytotoxicity of the compounds was tested in Vero
cells using two methods, namely, MTT and trypan blue
dye exclusion assay. Monolayers of uninfected cells were
incubated with culture medium containing different con-
centrations of compounds for 72 h at 37°C. The medium
was then removed, the cells trypsinized and viable cells
counted by trypan blue dye exclusion test. The 50% cyto-
toxic concentration (CC50) was calculated by linear
regression analysis of the dose-response curves generated
from these data. In the second method, monolayer of
Vero cells in 96-multiwell plates were incubated with
MTT (5 μg/mL) at 37°C for 4 h. After this period, SDS
10% and 0.01 N HCl were added to each well and incu-
bated overnight. The plates were read using an automatic
plate reader with a 540-nm test wavelength and a 690-
nm reference wavelength. Plaque reduction assay was
performed utilizing Vero cells at a density of 3 × 10
5
infected with various dilutions of the supernatant from a
yield reduction assay for 1 h at 37°C and 5% CO2.A f t e r
adsorption, the plates were washed and the medium was
replaced with DMEM containing methylcellulose 1% and
fetal bovine serum 5%. After incubation for 72 h, the
monolayers were fixed with 1% formaldehyde in PBS,
methylcellulose removed, and cell stained with a 0.1%
solution of crystal violet in 70% methanol. The virus yield
assay was performed as follows. Confluent Vero cells
were washed with PBS and infected with HSV-1 at moi
of 1 PFU/cell for 1 h at 37°C. The infected cells were
washed with PBS and covered with a culture medium
containing either no compounds or a different concen-
tration of compounds. 20 h after adsorption, cells were
lysed by freezing and thawing (three times), and the
supernatant consisting of culture medium and lysed cells
was obtained by centrifugation at 400g for 10 min at 4°C.
Virus titre was determined by the plaque assay in Vero
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by Student’s t-test for a significance level of p < 0.05.
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